



GASTROENTEROLOGY *LKA with Hepatology Focus*

Effective beginning with the 2026 Quarter 3 Longitudinal Knowledge Assessment.

High Relevance: Topics are very likely to appear on the assessment.

Medium Relevance: Topics are moderately likely to appear on the assessment.

Low Relevance: Topics will not appear on the assessment.

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 43%	Treatment/ Care Decisions 45%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 2%
1 Procedures and Periprocedural Issues	5%				
1.1 Gastrointestinal bleeding management	<2%	HIGH	HIGH	HIGH	HIGH
1.1.1 Resuscitation					
1.1.2 Transfusion					
1.1.3 Obscure					
1.2 Adverse effects of endoscopy	<2%	HIGH	HIGH	MEDIUM	MEDIUM
1.3 Safety and procedure logistics	<2%	HIGH	HIGH	HIGH	HIGH
1.3.1 Personal protective equipment					
1.3.2 Radiation safety					
1.3.3 Ergonomics					
1.3.4 Patient positioning					
1.3.5 Special populations (e.g., pregnant or immunosuppressed)					
1.4 Procedural indications and timing	<2%	HIGH	HIGH	HIGH	HIGH
1.4.1 Procedure timing					
1.4.2 Equipment selection					
1.4.3 Technique and sampling selection					
1.4.4 Lesion recognition					
1.4.5 Lesion management					
1.5 Quality measures	<2%	HIGH	HIGH	HIGH	LOW
1.5.1 Procedural surveillance intervals					
1.5.2 Procedural quality indicators					
1.6 Medication management	<2%	HIGH	HIGH	HIGH	HIGH
1.6.1 Periprocedural coagulopathy and anticoagulation management					
1.6.2 Periprocedural medications (e.g., antibiotics, glucagon-like peptide-1 receptor antagonists)					
1.7 Sedation and anesthesia-related issues	<2%	HIGH	HIGH	HIGH	HIGH
1.7.1 Cardiopulmonary and comorbidity assessment					
1.7.2 Adverse events					
1.7.3 Airway management					
1.8 Enteral access, including percutaneous endoscopic gastrostomy or percutaneous endoscopic jejunostomy tubes	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
1.9 Ethical and medical-legal considerations	<2%	MEDIUM	MEDIUM	MEDIUM	LOW
1.9.1 Informed consent					
1.9.2 Goals of care					
1.10 Endoscopic emergencies other than gastrointestinal bleeding	<2%	HIGH	HIGH	HIGH	MEDIUM
1.10.1 Foreign bodies					

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 43%	Treatment/ Care Decisions 45%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 2%
1.10.2 Perforations					
1.10.3 Cholangitis					
1.10.4 Volvulus and bowel obstructions					
2 Esophageal Disorders	4%				
2.1 Barrett esophagus	<2%	HIGH	HIGH	HIGH	MEDIUM
2.2 Eosinophilic esophagitis	<2%	HIGH	HIGH	MEDIUM	MEDIUM
2.3 Anatomic abnormalities of the esophagus	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
2.3.1 Inlet patches					
2.3.2 Extrinsic compression					
2.3.3 Rings, webs, and strictures					
2.4 Physiology of the esophagus	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
2.5 Gastroesophageal reflux	<2%	HIGH	HIGH	HIGH	HIGH
2.6 Oropharyngeal disorders	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
2.6.1 Anatomic					
2.6.2 Neuromuscular					
2.7 Foreign body and food impaction	<2%	HIGH	MEDIUM	MEDIUM	MEDIUM
2.8 Esophageal injury	<2%	HIGH	HIGH	MEDIUM	MEDIUM
2.8.1 Mallory-Weiss tears					
2.8.2 Medication, radiation, and caustic injuries					
2.8.3 Perforations					
2.9 Systemic disorders involving the esophagus	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
3 Gastric and Duodenal Disorders	4%				
3.1 Nausea and vomiting (e.g., cannabinoid hyperemesis)	<2%	HIGH	HIGH	HIGH	HIGH
3.2 Anatomic abnormalities of the stomach and duodenum	<2%	HIGH	HIGH	HIGH	MEDIUM
3.2.1 Congenital					
3.2.2 Acquired, including altered anatomy					
3.3 Physiology of the stomach and duodenum	<2%	HIGH	HIGH	MEDIUM	MEDIUM
3.4 Gastric outlet obstruction	<2%	HIGH	MEDIUM	MEDIUM	MEDIUM
3.5 Gastric mucosal disorders	<2%	HIGH	HIGH	HIGH	MEDIUM
3.5.1 Inflammatory					
3.5.2 Infectious					
3.5.3 Infiltrative					
3.5.4 Polyps					
3.6 Peptic ulcer disease	<2%	HIGH	HIGH	HIGH	HIGH
3.6.1 Helicobacter pylori infection					
3.6.2 Nonsteroidal anti-inflammatory drugs					
3.6.3 Complications					
3.7 Postsurgical conditions, including gastric resection and complications of bariatric surgery	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
3.8 Systemic disorders involving the stomach	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
4 Inflammatory Bowel Disease and Other Immune-Related Disorders	4.5%				

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 43%	Treatment/ Care Decisions 45%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 2%
4.1 Crohn disease	<2%	HIGH	HIGH	HIGH	HIGH
4.1.1 Small bowel and colon					
4.1.2 Upper gastrointestinal or perianal					
4.1.3 Extraintestinal manifestations					
4.1.4 Complications					
4.2 Ulcerative colitis	<2%	HIGH	HIGH	HIGH	HIGH
4.2.1 Extraintestinal manifestations					
4.2.2 Complications					
4.3 Celiac disease	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
4.3.1 Extraintestinal manifestations					
4.3.2 Complications					
4.4 Immunologic and inflammatory disorders of the gut	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
5 Motility Disorders	2%				
5.1 Esophageal	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
5.1.1 Achalasia					
5.1.2 Nonachalasia					
5.2 Gastric	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
5.2.1 Gastroparesis					
5.2.2 Rapid gastric emptying					
5.3 Small-bowel and colonic	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
5.3.1 Ileus					
5.3.2 Pseudo-obstruction					
5.4 Anorectal	<2%	MEDIUM	MEDIUM	MEDIUM	LOW
6 Neoplastic Disorders	13%				
6.1 Genetic cancer syndromes, including Lynch syndrome, familial adenomatous polyposis, familial atypical multiple mole melanoma syndrome, Peutz–Jeghers syndrome, and BRCA mutation	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
6.2 Neoplasms of the esophagus	<2%	HIGH	HIGH	HIGH	MEDIUM
6.2.1 Benign					
6.2.2 Malignant					
6.3 Neoplasms of the stomach	<2%	HIGH	HIGH	MEDIUM	MEDIUM
6.3.1 Benign					
6.3.2 Malignant					
6.4 Neoplasms of the small bowel	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
6.4.1 Benign					
6.4.2 Malignant					
6.5 Neoplasms of the liver	6.5%	HIGH	HIGH	HIGH	MEDIUM
6.5.1 Benign					
6.5.2 Malignant					
6.6 Neoplasms of the biliary tract	<2%	HIGH	HIGH	HIGH	MEDIUM
6.6.1 Benign					

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 43%	Treatment/ Care Decisions 45%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 2%
6.6.2 Malignant					
6.7 Neoplasms of the pancreas	<2%	HIGH	HIGH	HIGH	MEDIUM
6.7.1 Benign					
6.7.2 Malignant					
6.8 Neoplasms of the colon and rectum	<2%	HIGH	HIGH	HIGH	MEDIUM
6.8.1 Benign					
6.8.2 Malignant					
6.9 Neuroendocrine tumors	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
6.9.1 Benign					
6.9.2 Malignant					
6.10 Gastrointestinal manifestations of other cancers	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7 Liver Disorders	45.5%				
7.1 Anatomic abnormalities of the liver	<2%	HIGH	MEDIUM	MEDIUM	MEDIUM
7.2 Physiology of the liver	<2%	HIGH	HIGH	MEDIUM	MEDIUM
7.3 Liver diagnostic studies	3.5%	HIGH	HIGH	HIGH	HIGH
7.3.1 Liver biochemical studies					
7.3.2 Liver imaging					
7.3.3 Prognostic scores					
7.3.4 Liver biopsy					
7.3.5 Noninvasive liver disease assessment					
7.3.6 Portal pressure measurement					
7.4 Portal hypertension	6%	HIGH	HIGH	HIGH	MEDIUM
7.4.1 Varices					
7.4.2 Ascites and hepatic hydrothorax					
7.4.3 Hepatorenal syndrome					
7.4.4 Portosystemic encephalopathy					
7.4.5 Pulmonary complications					
7.4.6 Noncirrhotic					
7.5 Inherited disorders	2.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.5.1 Wilson disease					
7.5.2 Alpha1-antitrypsin deficiency					
7.5.3 Cystic fibrosis					
7.5.4 Sickle cell hepatopathy					
7.5.5 Hereditary hemochromatosis					
7.5.6 Progressive familial intrahepatic cholestasis and benign recurrent intrahepatic cholestasis					
7.6 Cholestatic liver diseases	2.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.6.1 Primary biliary cholangitis					
7.6.2 Primary sclerosing cholangitis					
7.6.3 Secondary sclerosing cholangitis					
7.7 Viral hepatitis	3.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 43%	Treatment/ Care Decisions 45%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 2%
7.7.1 Hepatitis A					
7.7.2 Hepatitis B					
7.7.3 Hepatitis C					
7.7.4 Hepatitis D					
7.7.5 Hepatitis E					
7.7.6 Other viral hepatitis (e.g., cytomegalovirus, Epstein–Barr virus, COVID-19, herpes simplex virus)					
7.8 Autoimmune hepatitis and overlap syndromes	2.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.9 Vascular liver disease	2.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.9.1 Presinusoidal vascular disorders					
7.9.2 Postsinusoidal vascular disorders					
7.9.3 Portosinusoidal vascular disorders					
7.9.4 Splanchnic thromboses					
7.9.5 Cardiopulmonary vascular disorders					
7.10 Alcohol-associated liver disease	3.5%	HIGH	HIGH	HIGH	MEDIUM
7.11 Metabolic dysfunction-associated steatotic liver disease	3.5%	HIGH	HIGH	HIGH	HIGH
7.12 Drug-induced liver injury	2.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.13 Pregnancy-related liver disease	<2%	HIGH	HIGH	HIGH	MEDIUM
7.14 Acute liver failure/acute liver injury and acute-on-chronic liver failure	2%	HIGH	HIGH	HIGH	HIGH
7.15 Nonviral liver infections	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.16 Hepatic manifestations of systemic disease	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.17 Liver transplantation	3.5%	HIGH	HIGH	HIGH	MEDIUM
7.17.1 Indications (e.g., alcohol use, alcohol-associated hepatitis)					
7.17.2 Complications (e.g., strictures)					
7.17.3 Post-transplantation management and adverse effects					
7.18 Surgery in patients with liver disease	<2%	HIGH	HIGH	HIGH	MEDIUM
7.19 Extrahepatic manifestations of liver disease	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
8 Pancreas and Biliary Tract Disorders	10%				
8.1 Gallbladder disease	<2%	HIGH	HIGH	HIGH	MEDIUM
8.2 Bile duct disease	5%	HIGH	HIGH	MEDIUM	MEDIUM
8.3 Anatomic abnormalities of the pancreas/biliary tract	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
8.4 Physiology of the pancreas/biliary tract	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
8.5 Pancreatic insufficiency	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
8.6 Acute pancreatitis	<2%	MEDIUM	HIGH	MEDIUM	MEDIUM
8.7 Chronic pancreatitis	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
9 Disorders of Gut–Brain Interaction	3%				
9.1 Functional esophageal disorders	<2%	HIGH	HIGH	MEDIUM	MEDIUM
9.2 Chronic nausea and vomiting syndromes	<2%	HIGH	HIGH	MEDIUM	MEDIUM
9.3 Functional dyspepsia	<2%	HIGH	HIGH	MEDIUM	MEDIUM
9.4 Abdominal distention, bloating, gas, and belching	<2%	MEDIUM	HIGH	MEDIUM	MEDIUM
9.5 Centrally mediated abdominal pain syndromes	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 43%	Treatment/ Care Decisions 45%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 2%
9.5.1 Abdominal migraine disorder					
9.6 Functional biliary-like pain	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
9.7 Irritable bowel syndrome	<2%	HIGH	HIGH	MEDIUM	MEDIUM
9.7.1 Irritable bowel syndrome with diarrhea					
9.7.2 Irritable bowel syndrome with constipation					
9.7.3 Irritable bowel syndrome with mixed symptomology					
9.8 Functional anorectal pain	<2%	MEDIUM	MEDIUM	MEDIUM	LOW
10 Nutrition	3%				
10.1 Vitamin and mineral deficiency and excess	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
10.2 Avoidant/restrictive food intake disorder	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
10.3 Digestion, malabsorption, and absorption	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
	<2%	HIGH	MEDIUM	MEDIUM	MEDIUM
10.5 Clinical nutrition (e.g. malnutrition assessment, frailty scores)	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
10.6 Enteral and parenteral nutrition	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
11 Other Disorders	6%				
11.1 Diarrheal syndromes	<2%	HIGH	HIGH	HIGH	HIGH
11.2 Small intestinal bacterial overgrowth	<2%	MEDIUM	HIGH	MEDIUM	MEDIUM
11.3 Anal disorders	<2%	HIGH	HIGH	MEDIUM	MEDIUM
11.4 Hernias, volvulus, intussusception, and bowel obstruction	<2%	HIGH	HIGH	MEDIUM	MEDIUM
11.5 Vascular disorders of the small bowel and colon	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
11.6 Appendicitis, small bowel, and colon infections	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
11.7 Postsurgical small bowel and colon conditions	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
11.8 Microscopic colitis	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
11.9 Colonic diverticulosis and complications	<2%	HIGH	HIGH	HIGH	MEDIUM
11.10 Intestinal manifestations of systemic disease	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
11.11 Abdominal wall and musculoskeletal pain	<2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM